BOSTON, Massachusetts, May 26, 2026
Ginkgo Bioworks, through its Ginkgo Datapoints platform, has announced the launch of ADME-One™, a new integrated high-throughput drug discovery platform developed in collaboration with Tangible Scientific and Inductive Bio. The platform combines automated Tier 1 ADME testing, AI-powered human pharmacokinetic (PK) prediction, and integrated compound management into a unified workflow designed to help pharmaceutical and biotechnology companies make better drug candidate decisions much earlier in the discovery process.
The launch reflects growing industry demand for faster, AI-enabled drug discovery systems capable of reducing development risk and improving efficiency during early-stage small molecule research. According to the companies, ADME-One™ is specifically designed to solve a longstanding challenge in pharmaceutical development where comprehensive absorption, distribution, metabolism, and excretion (ADME) profiling is often delayed until late-stage lead optimization due to cost and operational complexity. By moving advanced ADME analysis into the earliest phases of hit identification, the platform aims to reduce failed development programs, eliminate inefficient synthesis cycles, and improve selection of drug candidates most likely to succeed in human clinical studies.
ADME-One™ Integrates AI and Automated Drug Discovery
ADME-One™ combines three specialized technologies into a single workflow spanning laboratory automation, AI-driven pharmacokinetic modeling, and operational logistics. Ginkgo Datapoints will conduct the full suite of Tier 1 ADME assays at its automated laboratory facility in Boston, including microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding analysis.
The resulting data will then be processed using Inductive Bio’s Compass AI platform, which integrates experimental ADME results into predictive human pharmacokinetic models capable of estimating safe and effective human dosing profiles. Inductive Bio’s AI systems recently achieved top rankings in the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction competitions, strengthening confidence in the platform’s predictive capabilities.
Advertisement
Meanwhile, Tangible Scientific will manage compound logistics, intake, tracking, plating, and sample coordination through its compound management infrastructure. Company executives stated that integrating these traditionally separate processes into a single workflow significantly reduces operational bottlenecks and enables faster feedback between virtual AI-driven drug design and real-world laboratory validation.
AI-Powered Drug Discovery Targets Faster Development
Industry experts increasingly view AI-driven laboratory workflows as essential for modern pharmaceutical research due to the rising complexity of drug discovery and pressure to reduce development costs. Traditional ADME testing approaches often limit the number of compounds that can be evaluated early in discovery because of cost and infrastructure limitations.
John Androsavich, General Manager at Ginkgo Datapoints, stated that ADME-One™ fundamentally changes how drug discovery teams evaluate compounds during early-stage research by enabling chemists to rapidly profile entire molecular series rather than waiting until later optimization stages.
Executives from Tangible Scientific and Inductive Bio emphasized that many biotechnology companies already generate large volumes of AI-designed molecules but face operational and logistical challenges validating them efficiently in laboratory settings. The ADME-One™ platform is designed to bridge this gap through integrated automation, AI-driven prioritization, and rapid data turnaround.
The platform also aligns with broader pharmaceutical industry trends favoring domestic U.S.-based drug discovery infrastructure amid increasing concerns around supply chain resilience, data sovereignty, and evolving regulatory requirements linked to the BIOSECURE Act and global geopolitical uncertainty.
Pharmaceutical Industry Accelerates AI Laboratory Adoption
The launch of ADME-One™ highlights accelerating investment in AI-powered pharmaceutical development technologies, one of the fastest-growing sectors within biotechnology and life sciences. Pharmaceutical companies are increasingly adopting machine learning, robotics, and predictive modeling systems to reduce research timelines, lower costs, and improve clinical success rates.
Industry analysts believe integrated AI-laboratory platforms capable of generating standardized, high-volume biological data will become critical infrastructure for next-generation drug discovery. The ability to rapidly iterate between computational prediction and experimental validation is expected to play an increasingly important role in developing precision medicines and advanced therapeutics.
Ginkgo Bioworks also announced the appointment of Jonathan Grob as Vice President of Small Molecules within Ginkgo Datapoints, reinforcing the company’s long-term strategy to expand its AI-enabled drug discovery capabilities and strengthen leadership in automated pharmaceutical research technologies.
Source: Ginkgo Bioworks, Inductive Bio and Tangible press release
